X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (111) 111
humans (95) 95
animals (56) 56
pteridines - pharmacology (52) 52
protein-serine-threonine kinases - antagonists & inhibitors (45) 45
male (44) 44
cell cycle proteins - antagonists & inhibitors (42) 42
proto-oncogene proteins - antagonists & inhibitors (42) 42
female (37) 37
oncology (37) 37
mice (31) 31
pteridines - pharmacokinetics (31) 31
pharmacology & pharmacy (29) 29
cancer (27) 27
aged (25) 25
cell line, tumor (25) 25
pteridines - therapeutic use (24) 24
adult (23) 23
apoptosis (23) 23
middle aged (23) 23
chemistry, medicinal (20) 20
protein-serine-threonine kinases - metabolism (20) 20
cell cycle proteins - metabolism (19) 19
dose-response relationship, drug (19) 19
polo-like-kinase-1 (19) 19
proto-oncogene proteins - metabolism (19) 19
pteridines - administration & dosage (19) 19
biochemistry & molecular biology (18) 18
protein kinase inhibitors - pharmacology (18) 18
plk1 (16) 16
pteridines - adverse effects (16) 16
pteridines - chemistry (16) 16
rats (16) 16
neoplasms - drug therapy (15) 15
polo-like kinase (15) 15
treatment outcome (15) 15
tumors (15) 15
cells (14) 14
expression (14) 14
protein kinase inhibitors - therapeutic use (14) 14
therapy (14) 14
antineoplastic agents - pharmacokinetics (13) 13
chemotherapy (13) 13
volasertib (13) 13
antineoplastic agents - pharmacology (12) 12
bi 2536 (12) 12
hematology (12) 12
kinases (12) 12
protein kinase inhibitors - pharmacokinetics (12) 12
structure-activity relationship (12) 12
apoptosis - drug effects (11) 11
bi 6727 (11) 11
cancer-cells (11) 11
drugs (11) 11
enzyme inhibitors - pharmacology (11) 11
pteridines (11) 11
pteridines - metabolism (11) 11
toll-like receptor 7 - agonists (11) 11
administration, oral (10) 10
antineoplastic agents - therapeutic use (10) 10
bi-2536 (10) 10
cell biology (10) 10
cell proliferation - drug effects (10) 10
inhibitor (10) 10
phase-i (10) 10
proteins (10) 10
aged, 80 and over (9) 9
cell cycle (9) 9
cells, cultured (9) 9
polo (9) 9
advanced solid tumors (8) 8
analysis (8) 8
antineoplastic agents - adverse effects (8) 8
article (8) 8
cancer-therapy (8) 8
care and treatment (8) 8
cell cycle proteins - genetics (8) 8
chemistry, organic (8) 8
genetic aspects (8) 8
leukemia (8) 8
pharmacokinetics (8) 8
protein-serine-threonine kinases - genetics (8) 8
proto-oncogene proteins - genetics (8) 8
research (8) 8
selective inhibitor (8) 8
xenograft model antitumor assays (8) 8
acute myeloid-leukemia (7) 7
antineoplastic agents - administration & dosage (7) 7
blotting, western (7) 7
hematology, oncology and palliative medicine (7) 7
in-vitro (7) 7
infusions, intravenous (7) 7
inhibition (7) 7
inhibitors (7) 7
lung neoplasms - drug therapy (7) 7
maximum tolerated dose (7) 7
medicine & public health (7) 7
phosphorylation (7) 7
physiological aspects (7) 7
protein kinase inhibitors - administration & dosage (7) 7
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 05/2009, Volume 15, Issue 9, pp. 3094 - 3102
Purpose: Antimitotic chemotherapy remains a cornerstone of multimodality treatment for locally advanced and metastatic cancers. To identify novel... 
Polo-arrest | monopolar spindle | BI 6727 | Plk | Polo-like kinase inhibitor | CYTOKINESIS | CHEMICAL GENETICS | ONCOLOGY | POLO-LIKE-KINASE-1 | PLK1 | SPINDLE | MAMMALIAN-CELLS | DRUG TARGETS | CANCER-THERAPY | SMALL-MOLECULE INHIBITOR | REVEALS | Lung Neoplasms - drug therapy | Rats, Wistar | Apoptosis - drug effects | Pteridines - chemistry | Colonic Neoplasms - drug therapy | Humans | Crystallography, X-Ray | Lung Neoplasms - pathology | Forkhead Transcription Factors - physiology | Immunoenzyme Techniques | Cell Cycle Proteins - antagonists & inhibitors | Tissue Distribution | Enzyme Inhibitors - pharmacokinetics | Enzyme Inhibitors - chemistry | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Protein-Serine-Threonine Kinases - metabolism | Carcinoma, Non-Small-Cell Lung - pathology | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | Pteridines - pharmacology | Lung Neoplasms - enzymology | Cell Cycle Proteins - metabolism | Enzyme Inhibitors - pharmacology | Rats | Pteridines - pharmacokinetics | Antineoplastic Agents - chemistry | Blotting, Western | Xenograft Model Antitumor Assays | Animals | Mice, Nude | Colonic Neoplasms - pathology | Fluorescent Antibody Technique | Cell Line, Tumor | Protein Conformation | Cell Proliferation - drug effects | Colonic Neoplasms - enzymology | Mice | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Cell Cycle - drug effects | Index Medicus
Journal Article
Investigational New Drugs, ISSN 0167-6997, 6/2015, Volume 33, Issue 3, pp. 611 - 620
Background This trial evaluated the maximum tolerated dose (MTD), safety, pharmacokinetics, and activity of volasertib, a selective Polo-like kinase 1... 
Medicine & Public Health | Polo-like kinase inhibitor | Phase I trial | Oncology | Solid tumors | Pharmacology/Toxicology | Platinum therapy | Volasertib | CARBOPLATIN | VIVO | PLK1 | DOWN-REGULATION | CLINICAL PHARMACOKINETICS | COMBINATION | CELL LUNG-CANCER | SELECTIVE INHIBITOR | ONCOLOGY | BI 6727 | PHARMACOLOGY & PHARMACY | EXPRESSION | Antineoplastic Combined Chemotherapy Protocols - blood | Pteridines - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Pteridines - blood | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Pteridines - adverse effects | Male | Antineoplastic Agents - therapeutic use | Cell Cycle Proteins - antagonists & inhibitors | Dose-Response Relationship, Drug | Young Adult | Carboplatin - therapeutic use | Antineoplastic Agents - adverse effects | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Adult | Female | Antineoplastic Agents - pharmacokinetics | Protein-Serine-Threonine Kinases - metabolism | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | Platinum - therapeutic use | Cell Cycle Proteins - metabolism | Pteridines - pharmacokinetics | Neoplasms - drug therapy | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Adolescent | Antineoplastic Agents - blood | Aged | Infusions, Intravenous | Antimitotic agents | Complications and side effects | Dosage and administration | Research | Antineoplastic agents | Pharmacokinetics | Drug therapy | Tumors | Studies | Pharmaceutical industry | Research & development--R&D | International | Index Medicus | Phase I Studies
Journal Article
Journal Article
Blood, ISSN 0006-4971, 08/2014, Volume 124, Issue 9, pp. 1426 - 1433
Journal Article
Journal Article
British Journal of Cancer, ISSN 0007-0920, 05/2014, Volume 110, Issue 10, pp. 2434 - 2440
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 2, pp. 320 - 328
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 2/2016, Volume 34, Issue 1, pp. 66 - 74
Journal Article
Journal Article